Американское общество гирудотерапии

Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy

Mechanism study published in Blood (2011)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportКлинические исследованияФармакология секрета слюнных желёзWang H et al. · Blood, 2011

Abstract

Whereas it is generally perceived to be harmful, enhanced coagulation activation can also convey salutary effects. The high prevalence of the prothrombotic factor V Leiden (FVL) mutation in whites has been attributed to a positive selection pressure (eg, resulting from reduced blood loss or improved survival in sepsis). The consequences of enhanced coagulation activation, as observed in FVL carriers, on microvascular diabetic complications remain unknown. We therefore investigated the role of FVL in diabetic nephropathy. In heterozygous or homozygous diabetic FVL mice, albuminuria and indices of diabetic nephropathy were reduced compared with diabetic wild-type mice. This was associated with reduced glomerular apoptosis and preservation of podocytes in diabetic FVL-positive mice. In vitro, low-dose thrombin (50pM) prevented, whereas high-dose thrombin (20nM) aggravated, glucose-induced apoptosis in podocytes. In diabetic patients, the FVL mutation, but not the plasminogen activator inhibitor-1 4G/5G polymorphism, is associated with reduced albuminuria, which is consistent with a nephroprotective role of low but sustained thrombin generation. Consistently, anticoagulation of diabetic FVL-positive mice with hirudin abolished the nephroprotective effect. These results identify a nephroprotective function of low but sustained thrombin levels in FVL carriers, supporting a dual, context-dependent function of thrombin in chronic diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsApoptosisBlood CoagulationDiabetes Mellitus, ExperimentalDiabetic NephropathiesFactor VGenotypeGlucoseHumansHyperglycemiaImmunoblottingImmunohistochemistry

Резюме

Low-grade sustained coagulation activation via Factor V Leiden ameliorates glucose-induced podocyte apoptosis — supports hirudin therapeutic-window concept in DKD.

Почему это важно для гирудотерапии

This study investigated how factor V Leiden (FVL), a prothrombotic mutation, affects diabetic nephropathy, finding that low levels of coagulation activation can protect podocytes and reduce albuminuria in mice. Notably, when diabetic FVL mice were treated with the leech anticoagulant hirudin, this nephroprotective effect was abolished. This finding is highly relevant to the American Society of Hirudotherapy as it highlights a context-dependent interaction where leech-derived anticoagulants may counteract protective thrombin pathways in specific disease states. The limitation is that these findings are primarily derived from animal models and in vitro experiments, and do not reflect the typical therapeutic applications of hirudin.

Цитирование

Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.

Wang H et al. · Blood, 2011

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.